Simultaneous monitoring of amikacin and gentamycin levels in plasma versus prostatic fluid can predict thir in vivo therapeutic efficacy in chronic bacterial prostatitis

ABSTRACT

The study was conducted on 20 chronic bacterial prostatitis patients, they were divided into amikacin and gentamycin groups. They received therapeutic doses of i.m. twice daily amikacin and gentamycin. Their peak drug levels and pH measurements in plasma versus prostatic secretion were assessed after the first and last dose of the 7-day course together with post therapeutic bacteriological assessment. Results revealed a positive correlation between beneficial levels of the two aminoglycosides recovered in the prostatic fluid and the absence of bacterial growth in post therapeutic specimens. No definite relationship was correlated between drug levels and pH measurements in prostatic secretion. Therefore, performing initial quantitative detection of peak levels of aminoglycosides in the expressed prostatic secretion after the first dose was recommended, to determine whether the drugs are recovered in beneficial levels. So, the physician could take early decision whether to continue the course or to cut it short when the therapeutic value is not worth the hazards, costs and disappointment of inadequate response